Finance News World

Interstitial Lung Disease Market to Register Incremental Growth During the Forecast Period 2030 | Key Companies – Roche, aTyr Pharma. Galapagos, OncoArendi, and Others

 Breaking News
  • No posts were found

Interstitial Lung Disease Market to Register Incremental Growth During the Forecast Period 2030 | Key Companies – Roche, aTyr Pharma. Galapagos, OncoArendi, and Others

October 29
05:32 2021
Interstitial Lung Disease Market to Register Incremental Growth During the Forecast Period 2030 | Key Companies - Roche, aTyr Pharma. Galapagos, OncoArendi, and Others
Delveinsight Business Research LLP
DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Interstitial Lung Disease Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Interstitial Lung Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2017 to 2030. It evaluates the current treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Interstitial Lung Disease Market

Interstitial Lung Disease: An Overview

According to the American Lung Association, Interstitial Lung Disease is a general term for a large group of disorders that cause scarring or fibrosis of the lungs. Fibrosis or scarring can be part of the healing response to injury, but fibrosis as a disease process occurs when restoration to normal tissue does not occur. The scarring causes stiffness in the lungs, which makes it difficult to breathe. The disease is characterized by the presence of inflammation and altered-lung interstitium. ILDs usually have a gradual onset, but can also present an acute course, and lung damage from ILDs is irreversible and progressive; that means it gets worse over time.

Interstitial Lung Disease Market Key Facts

  • According to the research study of Black et al., the overall incidence of ILDs in the US was slightly more common in males (31.5 per 100,000/year) than females (26.1 per 100,000/year) for the study period of 1988–1990. The most common incident diagnosed among both sexes were pulmonary fibrosis and idiopathic pulmonary fibrosis, together accounting for 46.2% of all ILD diagnoses in males and 44.2% in females.

  • In a population-based study of Northern Europe, the reported overall incidence rate of ILDs was 31 per 100,000 for 2001–2005. The study observed a 33% increase in the incidence from 1995 to 2000. The increased incidence was observed in all age groups and both genders. (Kornum et al., 2008).

Get FREE sample copy at: Interstitial Lung Disease Therapeutics Market

Key Benefits of Interstitial Lung Disease Market Report

  • The report provides an in-depth analysis of Interstitial Lung Disease Market Size and Share till 2030 in the seven major markets.

  • The report will help in developing business strategies by understanding the Interstitial Lung Disease Market Trends, key players, and ongoing developments that shape and drive the market growth in the upcoming years.

  • It covers Interstitial Lung Disease current treatment practices, emerging drugs, market share of the individual therapies in the 7MM.

  • The report provides a detailed assessment of the Interstitial Lung Disease market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Interstitial Lung Disease Market 

The Interstitial Lung Disease market is expected to increase during the forecast period owing to the launch of upcoming therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Interstitial Lung Disease market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Interstitial Lung Disease market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Interstitial Lung Disease Epidemiology

The epidemiology section covers insights about the historical and current Interstitial Lung Disease patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Interstitial Lung Disease Epidemiology Subtype Segmentation

  • Total Incidence 

  • Gender-specific cases

  • Diagnosed and Treatable cases 

  • Subtype-specific cases (Unknown etiology, exogenous etiology, and variable etiology)

Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Lung Disease market or expected to get launched in the market during the study period. The analysis covers Interstitial Lung Disease market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Interstitial Lung Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Interstitial Lung Disease Therapeutics Analysis

Key companies in interstitial lung disease (ILD) Market Includes:

  • Roche

  • aTyr Pharma

  • Galapagos 

  • OncoArendi Pharmaceuticals

And others 

Interstitial Lung Disease Therapies covered in the report includes:

  • Pirfenidone

  • ATYR1923

  • Abatacept

  • OATD-01

And others

Request for Sample @ Interstitial Lung Disease Emerging Therapies and Key Companies

Table of Content

1. Key Insights

2. Executive Summary 

3. Interstitial Lung Disease Competitive Intelligence Analysis

4. Interstitial Lung Disease Market Overview at a Glance

5. Interstitial Lung Disease Disease Background and Overview

6. Interstitial Lung Disease Patient Journey

7. Interstitial Lung Disease Epidemiology and Patient Population

8. Interstitial Lung Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Interstitial Lung Disease Unmet Needs

10. Key Endpoints of Interstitial Lung Disease Treatment

11. Interstitial Lung Disease Marketed Products

12. Interstitial Lung Disease Emerging Therapies

13. Interstitial Lung Disease Seven Major Market Analysis

14. Attribute Analysis

15. Interstitial Lung Disease Market Outlook (7 major markets)

16. Interstitial Lung Disease Access and Reimbursement Overview

17. KOL Views on the Interstitial Lung Disease Market.

18. Interstitial Lung Disease Market Drivers

19. Interstitial Lung Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States